A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Tricaprilin (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms ALTER-AD
- Sponsors Cerecin
Most Recent Events
- 01 Apr 2026 New trial record